Awakn Announces Results of the World’s First ‘MDMA in Alcohol Use Disorder’ Trial Feb 22 • 3 min read Awakn Life Sciences Inc. announced the publication of results from its CMO Dr. Ben Sessa’s Bristol Imperial MDMA in Alcoholism (BIMA) trial.
Mindset Pharma Added to North American Psychedelics Index Feb 19 • 3 min read Mindset Pharma Inc. announced that it has been added to the North American Psychedelics Index.
Revive Therapeutics Acquires Unique Psilocybin Assets Feb 18 • 5 min read Revive Therapeutics Ltd. announced that it has entered into an asset purchase agreement with Newscope Capital Corporation to acquire the full rights to PharmaTher Inc.’s intellectual property pertaining to psilocybin.
MindMed’s LSD Neutralizer Study Begins Feb 17 • 5 min read MindMed announced the start of a study for its LSD neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session.
Mydecine Innovations Group Closes $17,250,000 Bought-Deal Public Offering Feb 15 • 3 min read Mydecine Innovations Group announced the closing of its previously-announced bought-deal public offering led by Canaccord Genuity Corp.